Mefloquine prevents malaria but has adverse effects that limit its acceptability in adults not immune to malarial infection


QUESTION
In adult travelers not immune to malarial infection, is mefloquine more effective than placebo or other prophylaxis for preventing malarial episodes and adverse events?

DATA SOURCES
Published and unpublished studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, and LILACS from 1966 to July 2000; the Cochrane Infectious Diseases Group (to July 2000); and Science Citation Index; by hand searching 2 medical medical journals {1945 to 1999}; and by hand searching for several subsequent issues the correspondence pages of journals yielding a published trial. Bibliographies of retrieved papers and standard textbooks of tropical medicine and conference proceedings were also searched. Personal contact was made with pharmaceutical companies, authors, and investigators.

STUDY SELECTION
Randomized or quasirandomized controlled trials were selected if participants were adults not immune to malaria, were prescribed prophylactic drugs for < 12 months, and were traveling to endemic malarious regions. Randomized tolerability studies were also included if they were done on pretravel or nontraveling volunteer participants. Studies were excluded if they examined a regimen no longer used for prophylaxis because of severe side effects.

DATA EXTRACTION
Data were extracted on participant characteristics, methods, details of intervention or placebo, outcomes, and study quality. Main outcome measures were malarial illness and withdrawal for any reason. Secondary outcomes were adherence at first assessment and reported symptoms.

MAIN RESULTS
10 trials met the selection criteria. Mefloquine was better than placebo (Table) but not other prophylaxis (1 case in 1 study) for preventing malarial episodes. Mefloquine was more likely than placebo (4 studies) to cause withdrawal from the study. Mefloquine was more likely than other prophylaxis to cause fatigue (4 studies) and insomnia (4 studies) (Table). Nonadherence at first assessment (4 studies), depression (3 studies), dreams (4 studies), headache (6 studies), diarrhea (6 studies), vomiting (4 studies), fever (2 studies), itch (3 studies), and nonmalarial death or hospitalization (2 studies) were also similar between mefloquine and other prophylaxis. Trial results for abdominal pain, anorexia, and nausea were heterogeneous.

CONCLUSION
In adult travelers not immune to malarial infection, mefloquine prevents malaria but has adverse effects that limit its acceptability.

Source of funding: Department for International Development UK.


*Information provided by author.

<table>
<thead>
<tr>
<th>Outcomes (1 study)</th>
<th>Comparison</th>
<th>Event rates</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria Mef vs Pl</td>
<td>0% vs 77%</td>
<td>100% (93 to 100)</td>
<td>2 (2 to 2)</td>
<td></td>
</tr>
<tr>
<td>Weighted event rates</td>
<td>RRI (CI)</td>
<td>NNH (CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Withdrawal Mef vs Pl</td>
<td>4.3% vs 1.2%</td>
<td>238% (62 to 603)</td>
<td>33 (21 to 72)</td>
<td></td>
</tr>
<tr>
<td>Fatigue Mef vs Other</td>
<td>7.9% vs 5.3%</td>
<td>50% (0 to 125)</td>
<td>39 (20 to 1000)</td>
<td></td>
</tr>
<tr>
<td>Insomnia Mef vs Other</td>
<td>14.7% vs 9.5%</td>
<td>55% (15 to 108)</td>
<td>20 (12 to 56)</td>
<td></td>
</tr>
</tbody>
</table>

**Mefloquine** (Me) vs **placebo** (Pl) or other prophylaxis (Other) in adult travelers not immune to malarial infection

COMMENTARY
Croft and Garner provide a sound systematic review of 10 randomized controlled trials on the chemoprophylactic effect of mefloquine in adults not immune to malaria. Analysis of the results confirms that mefloquine is better than placebo and its prophylactic effect is equivalent to that of other antimalarial drugs. The evaluated studies, however, are limited to a heterogeneous target population comprising military personnel and tourists, whose adherence to the treatment differs.

The authors showed that some side effects, such as fatigue and insomnia, occur more frequently in those receiving mefloquine than in those receiving other antimalarial drugs. The slow rate to achieve therapeutic blood concentrations, along with the long elimination half-life (13 to 26 days), leads to long periods of suboptimal blood concentrations, which may favor the appearance of mefloquine-resistant strains of the malaria parasite. This possibility as well as the safety, cost–benefit ratio, and therapeutic effectiveness of mefloquine demand further investigation. The cost of a 2-week prophylactic course of the drug is approximately U.S. $34.

We need to keep in mind that mefloquine and most of the other drugs used for malaria chemoprophylaxis are blood schizonticides that have no effect on sporozoites and the pre-erythrocytic forms that infect liver cells. Therefore, they prevent neither infection by mosquitoes nor the possibility of later relapses by *Plasmodium vivax* or *P. ovale*.

Until further information is available, it seems reasonable to prescribe mefloquine for malaria prophylaxis exclusively for persons who travel to areas of chloroquine-resistant malaria and who have no contraindications (e.g., no present or previous symptoms of seizures or psychiatric illness or an underlying cardiac conduction disturbance).

Leopoldo Santos-Neto, MD, PhD
Carlos Eduardo Tosta, MD, PhD
Universidade de Brasília
Brasília, DF, Brazil